Abstract

The objective: was to determine the frequency of cardiac symptoms in patients with stable angina pectoris with co-morbidity with gastroesophageal reflux disease (GERD) in the course of esophagogastroduodenofibroscopy (EHDS), determining the efficacy of Noophen®500 in order to prevent the development of cardiac symptoms of CHF, anxiety symptoms that may occur during ECGDS.Materials and methods. 89 patients with HF, I-II FC with comorbid endoscopically positive GERD (A, B, C) were examined. Two representative groups of the study were formed: group 1 (main group) – 45 patients who received a 500 mg dose of Noophen® 500 for a premedication, once a day, on the eve of EGGFS 2 hours before bedtime; 2nd (control) group – 44 patients who did not receive premedication. Endoscopic examination was carried out in the morning, on an empty stomach, 1 hour after awakening, under ECG monitoring. All patients before the use of the drug for 1 hour before the endoscopic examination and 1 hour after it, it was suggested to pass the tests of C.D. Spielberger and Yu.L. Hanina, and SUN. When conducting the efGDS, the possible effect of the drug on the technique of carrying out the endoscopic study was evaluated, and after diagnosis, the degree of satisfaction with the studies was determined in the patients surveyed.Results. A single application of Noophen® 500 can be recommended to prevent the occurrence of negative cardiac events during the endoscopic diagnosis, reduce the level of anxiety of patients, and provide a more comfortable diagnosis. Does not affect the state of sphincters, secretory and peristaltic activity of the digestive tract, facilitates the conduct of this diagnostic study for both the patient and the doctor.Сonclusion. The use of Noophen® 500 for the purpose of premedication provides an easy tranquilizing effect, anxiolytic, normotimic and moderate activating effects, improves mood, well-being and does not cause retardation, drowsiness, a feeling of exhaustion, and does not adversely affect the course of comorbid pathologies.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.